Avandia
FDA U-turn on Avandia
November 26, 2013Sales and Marketing Avandia, CDER, FDA, GSK, diabetes, nissen, type 2
The FDA has delivered a shock verdict that the stringent restrictions on GlaxoSmithKline’s diabetes medicine Avandia should be lifted, despite …
China accuses GSK of large scale bribery
July 12, 2013Medical Communications, Research and Development, Sales and Marketing Avandia, China, GSK, Seroxat
Health officials in China say they have found evidence GSK tried to generate sales and raise drug prices by bribing …
GSK slams Guardian article
January 31, 2013Sales and Marketing Avandia, FDA, GSK, Guardian
GlaxoSmithKline has slammed an article about its controversial diabetes treatment Avandia in The Guardian newspaper, saying that some of it …
Ethical dilemmas add to ‘critical weaknesses’ In FDA safety monitoring
August 25, 2012Sales and Marketing Avandia, Post-marketing surveillance, pharmacovigilance
Ethical challenges are central to continuing “critical weaknesses” in the FDA’s drug safety monitoring, according to a commentary by former …
GSK to pay ‘unprecedented’ $3 billion fraud charge
July 3, 2012Business Services, Sales and Marketing Avandia, Bextra, GSK, Paxil, Wellbutrin, Witty
GlaxoSmithKline will pay $3 billion in fraud charges, the largest of its kind in US history. The charges relate to …
EMA publishes updated diabetes guidelines
July 2, 2012Research and Development, Sales and Marketing Avandia, EMA, GSK, R&D, Takeda
The European Medicines Agency has published new guidance on what it wants to see from firms submitting new diabetes treatments. …
GSK profits slump amid ongoing Avandia woes
February 7, 2011Sales and Marketing 2010 pharma results, Avandia, GSK, GlaxoSmithKline
GlaxoSmithKline’s ongoing woes with diabetes drug Avandia hit profits in 2010. Profits after tax plummeted 56% to £3 billion for …
GSK settles Avandia case out of court
February 1, 2011Sales and Marketing Avandia, GSK, diabetes
GlaxoSmithKline this week settled a US federal lawsuit regarding its diabetes drug Avandia before it went to court. The company …
GSK takes £2.2bn hit from Avandia claims
January 18, 2011Sales and Marketing Avandia, GSK, GlaxoSmithKline, rosiglitazone
GlaxoSmithKline’s Avandia woes are continuing, with the company admitting it expects to take a mammoth legal charge over the troubled …
2010: Pharma’s year in review
December 23, 2010Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2010, Avandia, China, European healthcare spending, GSK, Obama, year in review
2010 saw a harsh new economic reality dominate decisions in the US and Europe, but pharma seized on opportunities in …
Revenue slump for GSK as Avandia sales stall
October 22, 2010Sales and Marketing Avandia, GSK, GlaxoSmithKline, UK science budget, patent box, pharma's 2010 results, pharma's Q3 results
GlaxoSmithKline has posted a third quarter loss after sales of its troubled diabetes drug Avandia and pandemic influenza products fell. …
Avandia should still be on the market, says GSK
October 7, 2010Sales and Marketing Avandia, GlaxoSmithKline
GlaxoSmithKline believes European regulators were wrong to withdraw its diabetes drug Avandia from the market, but will not challenge their …
Avandia withdrawn in Europe, but remains in US
September 24, 2010Sales and Marketing Avandia, FDA, pharmacovigilance, safety
GSK’s diabetes drug Avandia is to be withdrawn from the market in Europe because of high levels of heart attack, …
Pressure mounts on GSK over Avandia
September 6, 2010Sales and Marketing Avandia, GlaxoSmithKline
GlaxoSmithKline is under mounting pressure this week as calls intensify for its type II diabetes drug Avandia to be withdrawn …
Avandia letter misleading, FDA tells Glaxo
August 24, 2010Sales and Marketing Avandia, GSK
GlaxoSmithKline’s travails over controversial diabetes drug Avandia show no sign of abating as members of a key regulatory panel accused …
